Recruiting

Observational Study

Sponsor:

Vanderbilt University Medical Center

Code:

NCT07674758

Conditions

Duchenne Muscular Dystrophy (DMD)

Cardiomyopathy

Becker Muscular Dystrophy

Carrier of Duchenne Muscular Dystrophy

Eligibility Criteria

Sex: All

Age: 0+

Healthy Volunteers: Not accepted

Study Details

Brief summary:

Dystrophin associated heart dysfunction is a leading cause of death in patients with Duchenne and Becker Muscular dystrophy (DMD/BMD) and Duchenne and Becker muscular dystrophy carriers (MDC); however, the evolution of heart dysfunction is not well-understood. The central objectives of this proposal are to elucidate this evolution of heart dysfunction and identify measures from cardiac MRI images that can predict death or significant heart disease in patients with DMD/BMD/MDC. This study will create a large clinical and cardiac MRI registry of dystrophin associated heart dysfunction, will utilize advanced image analysis techniques, including deep learning neural networks, to comprehensively evaluate every patient, and will create a risk toolkit accessible to clinicians around the world; this proposal has the potential to improve the quality of life in patients with dystrophin associated heart dysfunction by allowing for earlier and more intensive therapy in patients with severe disease and by identifying surrogate outcome measures for use in therapeutic trials.

Conditions

Duchenne Muscular Dystrophy (DMD)

Cardiomyopathy

Becker Muscular Dystrophy

Carrier of Duchenne Muscular Dystrophy

Study ID

NCT07674758

Start date

Jan 6, 2025

Status verified date

Jul, 2026

Completion date

Feb 1, 2029

Anticipated

Primary completion date

Feb 1, 2029

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 0+

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • Clinical phenotype of Duchenne muscular dystrophy (DMD), Becker muscular dystrophy (BMD), or muscular dystrophy carrier (MDC) confirmed with muscle biopsy or genotype

Exclusion Criteria:

  • Additional genetic or congenital abnormality that may affect cardiovascular function or progression
  • Current investigational therapy that may affect cardiovascular function (would preclude ongoing data collection but prior data would still be used)

Study Design

Enrollment

1000 participants

Anticipated

Interventions and Outcome Measures

Arms

Duchenne Muscular Dystrophy, Becker muscular dystrophy, and carriers of muscular dystrophy

Evaluation of surrogate outcome measures of disease in patients with dystrophinopathy

Primary outcome measure

  • Mortality [ Time Frame: baseline to 10 years ]

Central Contacts and Locations

Central contacts

Locations

UC Davis

Recruiting

Sacramento, California, United States, 95616

Contacts

Children's National

Recruiting

Washington D.C., District of Columbia, United States, 20010

Contacts

Lurie Children's

Recruiting

Chicago, Illinois, United States, 60611

Contacts

Study Coordinator

312-227-4100

Riley Children's Hospital

Recruiting

Indianapolis, Indiana, United States, 46202

Contacts

Duke Children's Hospital

Recruiting

Durham, North Carolina, United States, 27705

Contacts

Nationwide Children's

Recruiting

Columbus, Ohio, United States, 43205

Contacts

Vanderbilt University Medical Center

Recruiting

Nashville, Tennessee, United States, 37232

Contacts

Children's Hospital of Richmond at VCU

Recruiting

Richmond, Virginia, United States, 23220

Contacts

Seattle Children's

Recruiting

Seattle, Washington, United States, 98105

Contacts

More Information

Sponsor

Vanderbilt University Medical Center

Last update posted

Jul 28, 2026

Last verified

Jul, 2026

Keywords

  • Duchenne Muscular Dystrophy
  • cardiomyopathy
  • machine learning
  • cardiac MRI
  • Biomarker
  • Outcome measures

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-09. This information was provided to ClinicalTrials.gov by Vanderbilt University Medical Center on 2026-07-28.